Perspective Therapeutics Inc Stock Price, News & Analysis

Perspective Therapeutics (NYSE AMERICAN: CATX) has received Fast Track Designation from the FDA for its 212Pb VMT01 product, targeting the diagnosis and treatment of unresectable or metastatic melanoma with MC1R tumor expression. This designation expedites development and review processes, offering more frequent FDA interactions and eligibility for accelerated approval, priority review, and rolling review.

The company has completed the observation period for dose-limiting toxicity in seven patients in Cohort 2 of its Phase 1/2a study. Perspective plans to share safety observations with the Safety Monitoring Committee and in a scientific forum later this year. Additionally, they intend to open a VMT01/anti-PD-1 combination cohort, pending institutional review board approval.

Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company focusing on advanced cancer treatments, has announced its participation in three upcoming investor conferences in September 2024. The company's senior leadership will be available for one-on-one meetings with investors at these events:

1. Morgan Stanley 22nd Annual Global Healthcare Conference on September 6 in New York, featuring a fireside chat.

2. 2024 Cantor Global Healthcare Conference on September 17 in New York, also with a fireside chat format.

3. 10th Annual World Medical Innovation Forum on September 24 in Boston, where Perspective will participate in a panel discussion on 'The Biologic Revolution in Radiotherapies'.

Webcasts of these events will be accessible live and archived for 90 days on the company's investor webpage.

Perspective Therapeutics (NYSE AMERICAN: CATX) reported fiscal Q2 2024 results and business highlights. Key points include:

• Completed enrollment of initial Cohort 2 patients in VMT-α-NET and VMT01 clinical trials
• On track to advance multiple pre-IND assets to clinic in 12-18 months
• Progressing on manufacturing infrastructure build-out
• $293 million cash balance expected to fund operations into mid-2026
• Q2 revenue: $0.5 million; R&D expenses: $9.3 million; G&A expenses: $5.5 million
• Net loss: $11.7 million or $0.18 per share

The company is advancing its radiopharmaceutical pipeline and manufacturing capabilities while maintaining a strong cash position to fund ongoing clinical and pre-clinical programs.

Perspective Therapeutics (NYSE AMERICAN: CATX), a pioneering radiopharmaceutical company, has announced its participation in two upcoming investor conferences in August 2024. The company's senior leadership team will be available for one-on-one meetings with investors at both events.

The first conference is the BTIG Virtual Biotechnology Conference, scheduled for August 5-6, 2024, which will be held virtually. The second is the 2024 Wedbush PacGrow Healthcare Conference, taking place in-person in New York, NY on August 13-14, 2024.

At the Wedbush conference, Perspective Therapeutics will also participate in a panel discussion titled 'Nuke 'em From Orbit: Radiotherapy' at 9:30am ET. This engagement highlights the company's focus on advanced treatment applications for cancers throughout the body using radiopharmaceuticals.

Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company focusing on advanced cancer treatments, has announced it will release its Q2 2024 financial results and provide a business update on August 12, 2024, after market close. The company, which specializes in pioneering treatment applications for various cancers, will make the press release available on their website's newsroom section. This announcement signals an important upcoming disclosure for investors and stakeholders, potentially offering insights into the company's financial performance and operational progress in the rapidly evolving field of radiopharmaceuticals.

Perspective Therapeutics (NYSE AMERICAN: CATX) announced its inclusion in the Russell 3000 Index, effective July 1, 2024. This annual reconstitution captures the 4,000 largest US stocks by market capitalization as of April 30. Perspective's inclusion also means potential membership in the Russell 1000 or Russell 2000 Index. CEO Thijs Spoor highlighted the company's recent clinical and corporate milestones as key factors for this recognition. The Russell indexes, used by investment managers for index funds and benchmarks, have around $10.5 trillion in assets as of December 2023.

Perspective Therapeutics (NYSE AMERICAN: CATX) has announced a 1-for-10 reverse stock split, effective June 14, 2024, at 4:01 p.m. Eastern time. Trading on a split-adjusted basis will begin on June 17, 2024. The reverse split will reduce the number of outstanding shares from approximately 674.3 million to 67.4 million. Stockholders approved the proposal at the annual meeting on May 31, 2024. The reverse split will not change the total number of authorized shares or the par values of the company's stock. Stockholders will receive cash for any fractional shares. All outstanding options and warrants will be adjusted accordingly.

Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company, announced six updates at the SNMMI 2024 Annual Meeting. Key updates include:

1. [212Pb]VMT-α-NET Phase I/IIa trial targeting neuroendocrine tumors showed a favorable safety profile.

2. Optimal imaging time for [203Pb]-VMT-α-NET was determined to be 4 hours post-injection.

3. First-in-human use of [212Pb]VMT-α-NET in India showed an encouraging tumor response, with a median PFS of 16.4 months.

4. Personalized dosimetry for [203Pb]VMT-α-NET and corresponding treatment plans for [212Pb]VMT-α-NET were discussed.

5. Pre-clinical studies on [212Pb]VMT01 for melanoma showed strong anti-tumor effects when combined with immune checkpoint inhibitors.

6. Novel peptide [203/212Pb]-PSV-359 showed promising anti-tumor activity in preclinical models.

Perspective Therapeutics (NYSE AMERICAN: CATX) announced the pricing of an $80 million underwritten offering of common stock and pre-funded warrants. The offering includes 51,515,880 common shares priced at $1.51 each and pre-funded warrants priced at $1.509 per warrant. The offering is expected to close by May 29, 2024, pending customary closing conditions. BofA Securities, Oppenheimer & Co., and RBC Capital Markets are joint book-runners, with B. Riley Securities as co-manager. Proceeds will support clinical development, manufacturing expansion, and general corporate purposes.